Lilly Reveals Details Of Presentations At ASCO Annual Meeting
Lilly Reveals Details Of Presentations At ASCO Annual Meeting
禮來在ASCO年會上透露演講細節
Eli Lilly said data from studies of Verzenio (abemaciclib; a CDK4/6 inhibitor), Retevmo (selpercatinib; a rearranged during transfection [RET] inhibitor), olomorasib (an investigational KRAS G12C inhibitor) and imlunestrant (an investigational oral selective estrogen receptor degrader [SERD]) will be presented at the meeting.
禮來公司說，來自Verzenio（abemaciclib；一種CDK4/6抑制劑）、Retevmo（selpercatinib；a）的研究數據 在轉染過程中重新排列 [休息] 抑制劑）、olomorasib（一種在研的KRAS G12C抑制劑）和imlunestrant（一種正在研究的口服選擇性雌激素受體降解劑 [SERD]）將在會上介紹。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。